Pharsight

Mitigare generic

Mitigare is a gout medication owned by Hikma Intl Pharms. It contains the active ingredient colchicine and was first authorized for market use on 26 September, 2014. The medication is available in a capsule;oral dosage form and has a total of 5 drug patents, none of which have expired.

When will Mitigare generic be available?

The generics of Mitigare are not yet available and are expected to be released after the expiration of the last patent on 22 August, 2033.

Mitigare uses

Mitigare is characterized by its effective use in the prophylaxis of gout flares, thanks to its active ingredient, colchicine.

Mitigare patent expiration

Mitigare holds a total of 5 patents, all titled 'Methods of colchicine administration' and each of them is set to expire on 22 August, 2033. Details of these patents can be found below:

Mitigare dosage

Want to ask something?